The use of anti-B cell therapy, which showed clinical efficacy in several patients with autoimmune diseases who also displayed elevated frequencies of autoreactive naive B cells in their blood may prevent the development of irAEs in CPI-treated cancer patients if given either prior to or shortly after administration of anti–CTLA-4 mAb. The gene discussed is CTLA4; the disease is autoimmune disease.